Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger
Rhea-AI Summary
Avanos Medical (NYSE: AVNS) and American Industrial Partners announced receipt of all required regulatory approvals for the pending acquisition of Avanos by AIP-advised funds. The merger is expected to close by July 27, 2026, pending Avanos stockholder approval and other customary closing conditions.
The special stockholder meeting to vote on the transaction is scheduled for July 22, 2026 at 9:00 a.m. ET in Atlanta.
Positive
- All required regulatory approvals for the AIP–Avanos merger have been obtained
- Expected merger closing by July 27, 2026, pending stockholder approval
- Special stockholder meeting set for July 22, 2026, providing a clear timeline
Negative
- Merger still contingent on Avanos stockholder approval
- Closing also depends on satisfaction or waiver of remaining closing conditions
News Market Reaction – AVNS
In the Jul 2 session, AVNS gained 1.22%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Acquisition announcement | Positive | +69.5% | Announced AIP buyout at $25.00 cash per share with large premium. |
| Oct 23 | Asset sale deal | Neutral | -0.3% | Agreed sale of US Game Ready orthopedic rental business with supply agreement. |
| Sep 15 | Business acquisition | Positive | +0.4% | Acquired Nexus Medical to strengthen critical-care nutrition and medication delivery. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Acquisition-related headlines for Avanos have generally seen price moves that align with the news tone, including one very large spike on the AIP buyout announcement.
Key Terms
regulatory approvals regulatory
merger regulatory
special meeting regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The proposed transaction is expected to close no later than July 27, 2026, subject to receipt of Avanos stockholder approval and the satisfaction or waiver of the remaining customary closing conditions. The special meeting of Avanos stockholders to approve the proposed transaction will be held on July 22, 2026, at 9:00 a.m., Eastern time, at the offices of Alston & Bird LLP, One Atlantic Center, 1201 West Peachtree Street,
"Securing all required regulatory approvals is a significant milestone and the result of strong collaboration between our two organizations," said David C. Pacitti, Chief Executive Officer of Avanos. "The receipt of these approvals brings us another step closer to completing the transaction with AIP and embarking on the next phase of innovation and growth at Avanos."
Joel Rotroff, Partner at AIP, said, "The receipt of regulatory approvals marks an important step towards completing this transaction. AIP is excited about the opportunity to partner with Avanos leadership and support the company's next phase of growth, innovation and commercial execution to deliver superior medical device solutions."
About Avanos Medical, Inc.
Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to what matters. Headquartered in
About American Industrial Partners
American Industrial Partners is an operationally oriented industrials investor with approximately
Important Additional Information
In connection with the Merger, Avanos has filed with the Securities and Exchange Commission (the "SEC") a definitive proxy statement on Schedule 14A and other materials with the SEC. Avanos may file or furnish other documents with the SEC regarding the Merger. INVESTORS AND STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND ACCOMPANYING PROXY CARD AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION.
Stockholders may obtain free copies of the proxy statement, any amendments or supplements to the proxy statement and other documents filed by Avanos with the SEC for no charge at the SEC's website at www.sec.gov. Copies will also be available at no charge at the Investors section of the Avanos' website at www.avanos.com.
Avanos, and its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from Avanos' stockholders in connection with Merger under the rules of the SEC. Detailed information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, are set forth in the proxy statement and will be set forth in the other relevant documents to be filed with the SEC in connection with the Merger when they become available. Information regarding the direct and indirect beneficial ownership of the Avanos' directors and executive officers in its securities is included in their SEC filings on Forms 3, 4 and 5, and additional information can also be found in Avanos' Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 24, 2026 and its definitive proxy statement for its 2026 annual meeting of stockholders filed with the SEC on March 12, 2026.
Forward-Looking Statements
This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "expect," "will," and similar expressions. These "forward-looking statements" include statements about the pending acquisition and related transactions, including the timing of the completion of the acquisition and the potential benefits of the acquisition. Forward-looking statements are based on the current plans and expectations of Avanos's management and are subject to various risks and uncertainties that could cause Avanos's actual plan and results to differ materially from those expressed or implied in such statements. Such factors include: (i) uncertainties as to the timing of the acquisition, (ii) the possibility that competing acquisition proposals will be made; (iii) the possibility that Avanos will terminate the merger agreement to enter into an alternative transaction; (iv) the possibility that various closing conditions for the transactions contemplated by the merger agreement may not be satisfied or waived; (v) the risk that the merger agreement may be terminated in circumstances requiring Avanos to pay a termination fee; (vi) the potential impact of the announcement or consummation of the proposed transactions on Avanos' relationships, including with employees, suppliers and customers; and (vii) the other factors and financial, operational and legal risks or uncertainties described in Avanos' public filings with the SEC, including the "Risk Factors" section of Avanos' Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as well as the proxy statement filed by Avanos in connection with the special meeting of stockholders in connection with the acquisition. The information contained herein speaks only as of the date of this release, and Avanos undertakes no obligation to update forward-looking statements, except as may be required by the securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-inc-and-american-industrial-partners-receive-required-regulatory-approvals-for-pending-merger-302816364.html
SOURCE Avanos Medical